Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry
Annals of Hematology · 2026
DOI: 10.1007/s00277-026-06743-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von C J M Halkes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Leiden University Medical Centre, Leiden, The Netherlands. c.j.m.halkes@lumc.nl. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Anemia, Aplastic, Registries, Immunosuppressive Agents. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Discussion remains concerning the safety and tolerability of anti-thymocyte globulin (ATG)-based immunosuppressive therapy (IST) in older patients with aplastic anaemia (AA). Using data of 127 consecutive patients from the Dutch adult AA registry, we evaluated long-term treatment success of standard ATG-based IST as first-line treatment with a multi-state model. Only one death was potentially associated with ATG. Overall survival at 5 years was 79%. We defined Transplantation-, Treatment- and Disease-Free Survival (TT-DFS) as the ultimate success of this treatment. This means that a patient is alive, is currently transfusion-independent without having received an allogeneic stem cell transplantation, has not developed AML or MDS, and has stopped all medication for AA. The probability of TT-DFS was 42% at 5 years after start of IST. In patients younger than 40 years ( n = 36) and in patients aged 60 or above ( n = 53), this was 58% and 34%, respectively. Older age, more severe AA and absence of a PNH-clone of ≥ 1% all reduced the likelihood of reaching TT-DFS. These analyses on unselected nationwide data indicate that ATG-based IST is effective and safe also in older patients. They suggest that age, AA severity and presence of a PNH-clone should be taken into account when considering this treatment in older patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, Leiden University Medical Centre, Leiden, The Netherlands. c.j.m.halkes@lumc.nl.
- Department of Haematology, Leiden University Medical Centre, Leiden, The Netherlands.
- Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Haematology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
- Department of Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Department of Haematology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Zitieren
APA
Halkes, C. J. M., Koster, E. A. S., Bogers, E. J. M., Heubel-Moenen, F. C. J. I., Daenen, L. G. M., Klein, S. K., Langemeijer, S. M. C., Nur, E., Raaijmakers, M. H. G., Snijders, T. J. F., Tjon, J. M. L., & de Wreede, L. C. (2026). Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry. Annals of Hematology. https://doi.org/10.1007/s00277-026-06743-5
Vancouver
Halkes CJM, Koster EAS, Bogers EJM, Heubel-Moenen FCJI, Daenen LGM, Klein SK, et al. Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry. Annals of Hematology. 2026. doi:10.1007/s00277-026-06743-5
BibTeX
@article{Halkes2026,
author = {Halkes, C J M and Koster, E A S and Bogers, E J M and Heubel-Moenen, F C J I and Daenen, L G M and Klein, S K and Langemeijer, S M C and Nur, E and Raaijmakers, M H G and Snijders, T J F and Tjon, J M L and de Wreede, L C},
title = {Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-06743-5}
}
EUVIMED